Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18082542 | 1.00 | BCHE (0.42) | BCHECARM1PRMT6ROCK2ROCK1 | |
| SCHEMBL25109164 | 0.89 | BCHE (0.40) | BCHECARM1PRMT6 | |
| SCHEMBL21660212 | 0.89 | CARM1 (0.34) | BCHECARM1PRMT6ROCK2ROCK1 | |
| SCHEMBL21654912 | 0.86 | BCHE (0.40) | BCHECARM1PRMT6DRD2DRD1 | |
| SCHEMBL10052290 | 0.85 | CARM1 (0.37) | CARM1PRMT6ROCK2ROCK1DRD2 | |
| SCHEMBL27283973 | 0.83 | PIK3CD (0.41) | BCHECARM1PRMT6KDM4E | |
| SCHEMBL18427493 | 0.83 | PIK3CD (0.41) | BCHECARM1PRMT6KDM4E | |
| SCHEMBL12436 | 0.83 | PIK3CD (0.41) | BCHECARM1PRMT6KDM4E | |
| SCHEMBL25922403 | 0.82 | BCHE (0.37) | BCHECARM1PRMT6DRD2DRD1 | |
| SCHEMBL12718206 | 0.82 | DRD4 (0.50) | BCHEDRD2DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130779-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200216490-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-07-09 | — | — | US | disclosed |
| US-10035819-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-07-31 | — | — | US | disclosed |
| US-8178531-B2 | Antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110218175-A1 | ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218175-A1 | ANTIVIRAL AGENTS | EIF2AK2, HAVCR2, MAVS | BCHE 3024/4885CARM1 4372/4885PRMT6 2646/4885 |
| US-20200216490-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | PPARD, PPARG, PPARA | BCHE 3055/4885CARM1 2532/4885PRMT6 3029/4885 |
| US-11130779-B2 | PPAR agonists and methods of use thereof | PPARD, PPARG, PPARA | BCHE 3055/4885CARM1 2532/4885PRMT6 3029/4885 |
| US-10035819-B2 | PPAR agonists and methods of use thereof | PPARD, PPARG, PPARA | BCHE 3055/4885CARM1 2532/4885PRMT6 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.